| __timestamp | Alpine Immune Sciences, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2287709 | 2983000000 |
| Thursday, January 1, 2015 | 6844000 | 3426000000 |
| Friday, January 1, 2016 | 8586000 | 3398000000 |
| Sunday, January 1, 2017 | 6079000 | 3878000000 |
| Monday, January 1, 2018 | 8362000 | 4056000000 |
| Tuesday, January 1, 2019 | 9467000 | 4381000000 |
| Wednesday, January 1, 2020 | 10899000 | 5151000000 |
| Friday, January 1, 2021 | 14560000 | 5246000000 |
| Saturday, January 1, 2022 | 17968000 | 5673000000 |
| Sunday, January 1, 2023 | 22222000 | 6090000000 |
| Monday, January 1, 2024 | 6091000000 |
Data in motion
In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Gilead Sciences, Inc. and Alpine Immune Sciences, Inc. have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Gilead, a titan in the industry, consistently reported SG&A expenses in the billions, peaking at approximately $6.1 billion in 2023. This represents a 104% increase from 2014, reflecting its expansive operations and market reach. In contrast, Alpine Immune Sciences, a burgeoning player, saw its SG&A expenses grow nearly tenfold, from $2.3 million in 2014 to $22.2 million in 2023. This surge underscores its aggressive growth strategy and increasing market presence. As these companies navigate the complexities of the biotech sector, their SG&A trends offer a window into their strategic priorities and operational challenges.
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and BeiGene, Ltd.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Incyte Corporation
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Pharming Group N.V.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Alkermes plc
Gilead Sciences, Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Gilead Sciences, Inc. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Viatris Inc. vs Alpine Immune Sciences, Inc.
Intra-Cellular Therapies, Inc. vs Alpine Immune Sciences, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Ascendis Pharma A/S and Alpine Immune Sciences, Inc.
Lantheus Holdings, Inc. and Alpine Immune Sciences, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Cytokinetics, Incorporated vs Alpine Immune Sciences, Inc.
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs Alpine Immune Sciences, Inc.